CJC-1295 calculators

The central characteristic of CJC-1295 is its division into two functionally separate variants: one with a Drug Affinity Complex (DAC) and one without. This structural difference is not a minor detail; it fundamentally alters the peptide's half-life from several minutes to approximately one week. Consequently, any plan to study or document this compound must begin by identifying which of the two distinct versions is being used, as their administration schedules diverge completely. Failure to distinguish between the 'with DAC' and 'no-DAC' forms is the most significant source of error when logging its use.

The no-DAC version is frequently referred to in research literature as Modified GRF (1-29) or Mod GRF 1-29. It is a tetra-substituted analog of Growth Hormone Releasing Hormone (GHRH) with a very short duration of action, similar to the peptide sermorelin. Because of its transient nature, it is almost universally studied in conjunction with a ghrelin mimetic like ipamorelin to produce a synergistic effect. In contrast, the DAC variant's long-acting profile allows for much less frequent administration, fundamentally changing how protocols are structured and documented.

The historical context for CJC-1295 originates with the Canadian biotechnology firm ConjuChem, which designed the compound in the early 2000s as part of a larger strategic platform. Its core innovation was not the base GHRH analog itself (a tetrasubstituted 29-amino-acid peptide), but the inclusion of its proprietary Drug Affinity Complex (DAC) technology. This platform was engineered with the broad objective of extending the circulating half-life of various therapeutic peptides and proteins, addressing a common challenge in peptide-based drug development. The primary goal was to decrease dosing frequency by enabling the molecule to bind covalently to serum albumin, a long-lived and abundant protein in the bloodstream. Thus, CJC-1295 with DAC should be understood as one specific application of a broader pharmaceutical research strategy focused on modifying the pharmacokinetic properties of biologics.

Both forms of CJC-1295 are analogs of GHRH and function by binding to and stimulating the Growth Hormone Releasing Hormone receptor (GHRHr) in the anterior pituitary gland. Stimulation of this receptor initiates the downstream cascade that results in the synthesis and release of growth hormone. The core peptide sequence responsible for this action is the first 29 amino acids of GHRH, which is what the 'no-DAC' variant (Mod GRF 1-29) comprises, with four specific amino acid substitutions to inhibit degradation.

The key divergence occurs with the addition of the Drug Affinity Complex. The DAC version includes a lysine residue linked to maleimidopropionic acid, which forms a covalent bond with the protein serum albumin after administration. This binding protects the peptide from enzymatic degradation by dipeptidyl peptidase-4 (DPP-IV) and dramatically reduces its clearance rate by the kidneys. This novel mechanism effectively turns circulating albumin into a temporary carrier for the peptide, extending its biological half-life from mere minutes to a span of 6-8 days.

The mechanism responsible for the extended duration of CJC-1295 with DAC involves a precise and stable chemical modification. The DAC component is a specialized maleimidopropyl group that is chemically reactive towards thiol groups, such as those found on cysteine residues within proteins. In the bloodstream, this group selectively forms a strong, covalent bond with a specific cysteine residue (Cys34) of circulating albumin. Once this bond is formed, the large albumin protein effectively acts as a carrier vehicle, sterically shielding the much smaller GHRH analog from rapid enzymatic degradation and renal clearance. This process of 'albumin-hitching' is what transforms the peptide's kinetic profile, increasing its half-life from minutes to several days, a central concept researchers study when they observe its long-term activity.

Protocols developed for the no-DAC version (Mod GRF 1-29) are defined by frequent administration due to its rapid clearance. Dosing schedules often involve one to three administrations per day to create distinct pulses of GH release, with a common example dose being 100 mcg per instance, leading to a schedule of 7 or more administrations per week. This variant is almost always paired with a Ghrelin Receptor Agonist (a GHRP like ipamorelin) in the same syringe to amplify the pituitary's response through a secondary receptor pathway.

Conversely, protocols for CJC-1295 with DAC are structured around its long half-life, requiring much less frequent administration. A typical research schedule might involve a single administration once or twice per week, with doses that are correspondingly larger to maintain elevated GH and IGF-1 levels over the interval. The choice between these two protocols is absolute; applying a daily dosing schedule intended for the no-DAC version to the long-acting DAC version would be a significant protocol error, and vice versa.

Divergent study designs directly reflect the profound pharmacokinetic differences between the two CJC-1295 variants. Research protocols involving the no-DAC version, sometimes referred to as Mod GRF 1-29, typically schedule administrations on a daily or even multi-daily basis to account for its very short half-life and maintain stable levels for observation. As a numeric example for personal tracking, a 2 mg vial reconstituted with 2 mL would yield a concentration of 1,000 mcg/mL; a 100 mcg illustrative dose is 0.1 mL or 10 units on a U-100 syringe, logged on a daily cadence (no-DAC variant). In stark contrast, studies observing the DAC variant plan for a much lower administration frequency, often weekly, to align with its long-lasting presence in circulation.